Lysogene Selects Brammer Bio to Produce GM1 Gangliosidosis Gene Therapy Product – Business Wire (press release)
|
Lysogene Selects Brammer Bio to Produce GM1 Gangliosidosis Gene Therapy Product
Business Wire (press release) Lysogene (Paris:LYS) (FR0013233475 – LYS), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it has entered into a strategic manufacturing agreement with … |
